EUVIMEDEUVIMED entdecken
Open Access

Enhanced delivery of camptothecin to colorectal carcinoma using a tumor-penetrating peptide targeting p32

Yanhao Jiang, Zhiren Wang, Wenpan Li, Teng Ma, Mengwen Li, Shuang Wu, Ethan Lin, Karlie Elizabeth Flader, Mengjiao Ma, Mengyang Chang, Hongmin Li, Wei Wang und 1 weitere

Acta Biomaterialia · 2025-06 · 200 · 629-640

DOI: 10.1016/j.actbio.2025.05.036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025-06. Verfasst von Yanhao Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 East…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cell-Penetrating Peptides, Camptothecin, Drug Delivery Systems. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIEHS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Camptothesome, a sphingomyelin (SM)-conjugated camptothecin (CPT) vesicular nanotherapeutic, addresses the poor solubility and lactone instability of CPT while enhancing drug loading, pharmacokinetics, and tumor distribution compared to CPT physically entrapped in conventional liposomes. Despite these improvements, the tumor uptake remains limited. To further enhance the tumor delivery efficiency and minimize the off-target distribution, we functionalize Camptothesome with the LinTT1 peptide, a CendR motif, which binds to overexpressed p32 proteins on tumor cell surface, initiating effective transcytosis for deep tumor penetration. Via systematic screening, the optimal peptide ratio on Camptothesome is identified. LinTT1/Camptothesome significantly increases cancer cell uptake without affecting normal cell internalization, resulting in enhanced anti-colorectal cancer cells activity. Additionally, decorating Camptothesome with the LinTT1 cell-penetrating peptide enables effective transcytosis via a Golgi-dependent intracellular trafficking mechanism, significantly improving the intratumoral delivery while reducing distribution to normal tissues. In a human HCT116 xenograft colorectal cancer (CRC) mouse model, LinTT1/Camptothesome demonstrates superior antitumor efficacy compared to both Camptothesome and Onivyde by upregulating cleaved caspase-3 and γH2AX. Our study substantiates the potential of leveraging a tumor-penetrating peptide to enhance the tumor delivery efficiency of Camptothesome, maximizing its therapeutic index for improved treatment of human CRC. STATEMENT OF SIGNIFICANCE: Despite the improved tumor delivery achieved by Camptothesome, its tumor distribution and penetration remain limited. This is because the enhanced permeability and retention effect only facilitates nanotherapeutic distribution to tumor periphery through leaky vasculature. The C-end Rule (CendR) motif-neuropilin receptor system enhances tumor-homing peptides by binding to cellular surface receptors, triggering transcytosis. Herein, LinTT1, the most potent CendR peptide that binds to the overexpressed p32 receptor on cancer cells, was effectively engineered onto Camptothesome using thiol-maleimide lipid chemistry. The LinTT1/Camptothesome significantly enhanced tumor uptake and penetration while minimizing accumulation in normal tissues, demonstrating remarkable anticancer efficacy in a human xenograft colorectal cancer model. Our findings highlight the critical role of tumor-homing peptides in unlocking the full therapeutic potential of Camptothesome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCell-Penetrating PeptidesCamptothecinDrug Delivery SystemsNeoplasm ProteinsHumansAnimalsHCT116 CellsMiceMice, NudeXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CamptothesomeColorectal cancerNanotherapeuticsTumor-homing LinTT1 peptidep32

Substanzen

Cell-Penetrating PeptidesCamptothecinNeoplasm Proteins

Autor:innen und Institutionen

  • Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 East Mabel Street, Tucson, AZ 85721, United States.
  • Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, 1703 East Mabel Street, Tucson, AZ 85721, United States; Clinical and Translati…

Förderung

  • NCI NIH HHS
  • NIEHS NIH HHS
  • NIGMS NIH HHS
  • Foundation for the National Institutes of Health
  • National Institutes of Health
  • The University of Arizona
  • National Cancer Institute
  • National Institute of Environmental Health Sciences

Zitieren

APA

Jiang, Y., Wang, Z., Li, W., Ma, T., Li, M., Wu, S., Lin, E., Flader, K. E., Ma, M., Chang, M., Li, H., Wang, W., & Lu, J. (2025). Enhanced delivery of camptothecin to colorectal carcinoma using a tumor-penetrating peptide targeting p32. Acta Biomaterialia, 200, 629-640. https://doi.org/10.1016/j.actbio.2025.05.036

Vancouver

Jiang Y, Wang Z, Li W, Ma T, Li M, Wu S, et al. Enhanced delivery of camptothecin to colorectal carcinoma using a tumor-penetrating peptide targeting p32. Acta Biomaterialia. 2025;200:629-640. doi:10.1016/j.actbio.2025.05.036

BibTeX
@article{Jiang2025,
  author = {Jiang, Yanhao and Wang, Zhiren and Li, Wenpan and Ma, Teng and Li, Mengwen and Wu, Shuang and Lin, Ethan and Flader, Karlie Elizabeth and Ma, Mengjiao and Chang, Mengyang and Li, Hongmin and Wang, Wei and Lu, Jianqin},
  title = {Enhanced delivery of camptothecin to colorectal carcinoma using a tumor-penetrating peptide targeting p32},
  journal = {Acta Biomaterialia},
  year = {2025},
  volume = {200},
  pages = {629--640},
  doi = {10.1016/j.actbio.2025.05.036}
}
Kostenlos starten →